PSI CRO AG
PSI CRO AG is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at PSI CRO AG.
PSI CRO AG is a company.
Key people at PSI CRO AG.
Key people at PSI CRO AG.
PSI CRO AG is a privately owned, full-service global Contract Research Organization (CRO) headquartered in Zug, Switzerland, specializing in planning and executing Phase II and III pivotal registration clinical trials across multiple therapeutic areas.[1][2][3][6] With 3,000 full-time employees operating in 56 countries, PSI reported 15% revenue growth in 2024, on-time project delivery above 90%, and a global staff turnover rate of just 9%, serving pharmaceutical, biotechnology, medical companies, universities, and government institutions through services like clinical research, data management, project management, and laboratory support.[1][2][3] The company boasts a 90% repeat and referral business rate, emphasizing reliability in an industry plagued by delays and high turnover.[1][6]
Founded in 1995 in Switzerland, PSI CRO AG has grown organically for 30 years under its original, unchanging management team, remaining the only fully independent and privately owned CRO of its size.[1][6] From its inception, PSI targeted the clinical research industry's core challenge: poor patient enrollment, which affects 90% of trials.[1][6] Early focus on organic growth and stability enabled global expansion to 56 countries, with headquarters at Baarerstrasse 113a, Zug.[1][4][5] Pivotal moments include consistent on-time delivery and earning CRO Leadership Awards for six consecutive years in expertise, quality, and reliability, as voted by sponsors.[6][7]
PSI CRO rides the wave of accelerating biopharma innovation, particularly in complex therapeutics like cell & gene therapy, radiopharmaceuticals, and rare diseases, where timely Phase II/III trials are critical for regulatory approval and market entry.[5][7] Its timing aligns with post-pandemic demand for faster, predictable enrollment amid global supply chain strains and talent shortages in clinical research—issues PSI counters with organic growth and low turnover.[1] Market forces favoring PSI include rising outsourcing to CROs (as in-house pharma capabilities shrink) and AI-driven tools like VISIONAL™ that optimize feasibility amid regulatory pressures from FDA/EMA.[6][7] By enabling on-time trials, PSI influences the ecosystem, speeding therapies to patients and supporting smaller biotechs lacking internal expertise.[1][3]
In 2025—its 30th year—PSI's momentum positions it for continued double-digit growth, leveraging GenAI enhancements and global footprint to capture share in high-growth areas like oncology and gene therapies.[1][7] Trends like AI protocol optimization, radiopharma expansion, and decentralized trials will amplify its edge, potentially pushing employee count beyond 3,000 while maintaining sub-10% turnover.[1][7] As biopharma consolidates outsourcing, PSI's independence and reliability could elevate its influence, drawing more referrals and setting benchmarks for CRO stability in a volatile sector—proving that in clinical trials, trust truly delivers results.
